Table 3 Current reports on daratumumab for PRCA.

Weverling et al.

14

AML, MDS, MPN, SCD, lymphoma

rituximab (43%), DLI (29%), bortezomib (7%)

1800 mg SC

1–6

60–2989

93% (defined by achievement of reticulocytosis), no relapse

Longval et al.

11

AML, MDS, MPN, SAA, DADA2

rituximab, EPO, thrombopoietin receptor agonist

7 with IV and 4 with SC

Median of 3

Median of 255

91% (defined by transfusion independence)

Giammarco et al.

6

Hematological diseases

rituximab, EPO, thrombopoietin receptor agonist

1800 mg SC

2

NA

83% (defined by transfusion independence)

Frioni et al.

3

NR

EPO, plasma exchange, rituximab

1800 mg SC

2–8

100–180

2 responses, 1 with no response after 8 doses

Desai et al.

3

AA, AML

Tapering of IS, IVIG, rituximab, steroids, plasma exchange, bortezomib

2 IV and 1 SC

4–6

180–730

100%

Chapuy et al.

1

MDS

tapering of IS, steroids, rituximab, darbepoetin

16 mg/kg IV

6

390

After first dose

Bathini et al.

1

SAA

Tapering of IS, Steroids, rituximab, bortezomib

16 mg/kg IV

4

411

After first dose

Rautenberg et al.

1

AML

Tapering of IS, rituximab

16 mg/kg IV

2

206

After second dose

Salas et al.

1

AA

Tapering of IS, rituximab, steroids, plasma exchange bortezomib

16 mg/kg IV

6

700

After 6^th dose

Henig et al.

1

Chronic neutropenia

Tapering of IS, rituximab, bortezomib

16 mg/kg IV

5

320

After 4^th dose

Yates et al.

1

DOCK8 deficiency

Tapering of IS

16 mg/kg IV

3

397

After third dose

Martino et al.

2

AML, MDS

NR

16 mg/kg IV

2, 3

205, 270

After first and second dose

Asawapanumas et al.

1

AML

Tapering IS

16 mg/kg IV

1

146

After first dose

Wu et al.

1

MDS

Tapering IS, rituximab

16 mg/kg IV

3

209

After second dose

Deng et al.

1

AML

Tapering IS, plasma exchange, interferon, MSC

16 mg/kg IV

5

2701

After second dose

Dovern et al.

1

SCD

None

1800 mg SC

4

60

After second dose